Associations between per- and poly-fluoroalkyl substance (PFAS) exposure and immune responses among women in the California Teachers study: A cross-sectional evaluation

[Display omitted] •PFAS exposures are linked to differences in systemic immune markers.•Immune marker associations are specific to PFAS analytes.•Elevated PFAS levels are linked to elevated levels of B-cell activating factor. Per- and polyfluoroalkyl substances (PFAS) are persistent environmental co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cytokine (Philadelphia, Pa.) Pa.), 2024-12, Vol.184, p.156753, Article 156753
Hauptverfasser: Cauble, Emily L., Reynolds, Peggy, Epeldegui, Marta, Andra, Syam S., Magpantay, Larry, Narasimhan, Srinivasan, Pulivarthi, Divya, Von Behren, Julie, Martinez-Maza, Otoniel, Goldberg, Debbie, Spielfogel, Emma S., Lacey, James V., Wang, Sophia S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •PFAS exposures are linked to differences in systemic immune markers.•Immune marker associations are specific to PFAS analytes.•Elevated PFAS levels are linked to elevated levels of B-cell activating factor. Per- and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants that have been linked to a number of health outcomes, including those related to immune dysfunction. However, there are limited numbers of epidemiological-based studies that directly examine the association between PFAS exposure and immune responses. In this cross-sectional study nested in the California Teachers Study cohort, we measured nine PFAS analytes in serum. Of the 9 analytes, we further evaluated four (PFHxS [perfluorohexane sulfonate], PFNA [perfluorononanoic acid], PFOA [perfluorooctanoic acid], PFOS [perfluorooctanesulfonic acid]) that had detection levels of > 80 %, in relation to 16 systemic inflammatory/immune markers and corresponding immune pathways (Th1 [pro-inflammatory/macrophage activation], B-cell activation, and T-cell activation). Study participants (n = 722) were female, completed a questionnaire regarding various health measures and behaviors, and donated a blood sample between 2013–2016. The association between PFAS analytes and individual immune markers and pathways were evaluated by calculating odds ratios (OR) and 95 % confidence intervals (CI) in a logistic regression model. PFAS analytes were evaluated both as a dichotomous exposure (above or below the respective median) and as a continuous variable (per 1 unit increase [ng/mL]). The prevalence of detecting any PFAS analyte rose with increasing age, with the highest PFAS prevalence observed among those aged 75 + years and the lowest PFAS prevalence observed among those aged 40–49 years (study participant age range: 40–95 years). Significant associations with BAFF (B-cell activating factor) levels above the median were observed among participants with elevated (defined as above the median) levels of PFHxS (OR=1.53), PFOA (OR=1.43), and PFOS (OR=1.40). Similarly, there were statistically significant associations between elevated levels of PFHxS and TNFRII (tumor necrosis factor receptor 2) levels (OR=1.78) and IL2Rα (interleukin 2 receptor subunit alpha) levels (OR=1.48). We also observed significant inverse associations between elevated PFNA and sCD14 (soluble cluster of differentiation 14) (OR=0.73). No significant associations were observed between elevated PFNA and a
ISSN:1043-4666
1096-0023
1096-0023
DOI:10.1016/j.cyto.2024.156753